Fig. 2From: A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancerCharacterization of nDCB via A DLS and (inset) TEM reveals particles of 45 nm in diameter. Release kinetics B at 37 °C under constant agitation demonstrates sustained release. Size (C), zeta potential and polydispersity index (PDI) D remain stable over the course of 2 months stored at 4 °CBack to article page